

## MARKET RELEASE

### MedAdvisor's H2 US results outperform expectations

*Adheris' H2 revenue to October up 74%+ YOY*

Melbourne, Australia, 23 November, 2020 - Medtech company MedAdvisor Limited (ASX: MDR) today reports second half results to-date for its newly acquired Adheris subsidiary, are stronger than expected.

#### Performance highlights

- Adheris' second half results to-date (October) are higher than planned and significantly higher than the same time last year (+74% vs H2 revenue to date FY19)
- First 4 months of H2 revenue FY20 USD \$10.9m vs USD \$6.3m FY19
- First 4 months of FY20 sales already exceeded H2 FY19 total sales of USD \$10.4 million
- MDR H2 revenue forecast for Adheris was USD \$13.8m

After successfully completing the acquisition of Adheris this month, the company's sales performance has already exceeded MedAdvisor's initial expectations for H2 and is up year-on-year +74% for the four months ended 31 October.

MedAdvisor's US President, John Ciccio, commented on the results saying: "We have recorded strong performance in H2 with October being our biggest month in the past two years. These results have set us up for strong momentum to see out the remainder of the financial year. Under MedAdvisor's ownership, we're excited to have the focus and investment to grow the Adheris business, providing tech-driven offerings to our clients."

This document has been authorised for release by Carlo Campiciano, MedAdvisor Company Secretary.

- ENDS -

#### For more information:

Simon Glover  
Chief Financial Officer  
[corporate@medadvisor.com.au](mailto:corporate@medadvisor.com.au)  
+61 3 9095 3036

Alex Beashel  
Corporate Communications  
[ab@alexbeashel.com](mailto:ab@alexbeashel.com)  
+61 466 308 667

#### About MedAdvisor

*MedAdvisor is a world-class medication management platform that empowers users to more simply manage their medication and improve adherence. MedAdvisor's highly automated and intuitive software system connects users to tools and education materials from their local/preferred pharmacy. In Australia, MedAdvisor has connected over 1.6 million users through more than 60% of Australian pharmacies and a network of thousands of GPs. MedAdvisor has recently partnered with HMS in the US, Zuellig Pharma in Asia and launched into the UK on track to become one of the largest players in the global digital adherence market. In 2018 and 2020, MedAdvisor was recognised in the AFR Fast 100. Visit: [mymedadvisor.com/investors](https://mymedadvisor.com/investors)*